{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:18:17Z","timestamp":1792642697589,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,12]],"date-time":"2018-10-12T00:00:00Z","timestamp":1539302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jphs.2018.10.004","type":"journal-article","created":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T21:12:07Z","timestamp":1539551527000},"page":"203-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-angiogenic effects of valproic acid in a mouse model of oxygen-induced retinopathy"],"prefix":"10.1016","volume":"138","author":[{"given":"Naoto","family":"Iizuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Kuroyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2018.10.004_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197713020-00001","article-title":"Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy","volume":"13","author":"Pinder","year":"1977","journal-title":"Drugs"},{"key":"10.1016\/j.jphs.2018.10.004_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00343800","article-title":"Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders","volume":"229","author":"Emrich","year":"1980","journal-title":"Arch Psychiatr Nervenkr (1970)"},{"key":"10.1016\/j.jphs.2018.10.004_bib3","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1248\/cpb.25.2257","article-title":"Effects of sodium dipropylacetate on gamma-aminobutyric acid and biogenic amines in rat brain","volume":"25","author":"Kukino","year":"1997","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.jphs.2018.10.004_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0014-2999(93)90266-K","article-title":"Magnesium valproate attenuates hyperactivity induced by dexamphetamine-chlordiazepoxide mixture in rodents","volume":"237","author":"Cao","year":"1993","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2018.10.004_bib5","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"G\u00f6ttlicher","year":"2001","journal-title":"EMBO J"},{"key":"10.1016\/j.jphs.2018.10.004_bib6","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"Suppl","key":"10.1016\/j.jphs.2018.10.004_bib7","first-page":"S91","article-title":"Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases","volume":"83","author":"G\u00f6ttlicher","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jphs.2018.10.004_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.onc.1205108","article-title":"Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling","volume":"21","author":"Deroanne","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jphs.2018.10.004_bib9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/mol.65.3.520","article-title":"Valproic acid inhibits angiogenesis in\u00a0vitro and in\u00a0vivo","volume":"65","author":"Michaelis","year":"2004","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jphs.2018.10.004_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1021\/mp800178b","article-title":"N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis","volume":"6","author":"Kim","year":"2009","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jphs.2018.10.004_bib11","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2176\/nmc.52.186","article-title":"Valproic acid inhibits angiogenesis in\u00a0vitro and glioma angiogenesis in\u00a0vivo in the brain","volume":"52","author":"Osuka","year":"2012","journal-title":"Neurol Med Chir (Tokyo)"},{"key":"10.1016\/j.jphs.2018.10.004_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3892\/mmr.2013.1834","article-title":"Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi-1 leukemia cells","volume":"9","author":"Zhang","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jphs.2018.10.004_bib13","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/exd.13159","article-title":"Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism","volume":"26","author":"Hrgovic","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jphs.2018.10.004_bib14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1089\/jop.2016.0017","article-title":"Effect of histone deacetylase inhibitor, butyroyloxymethyl-diethyl phosphate (AN-7), on corneal neovascularization in a mouse model","volume":"33","author":"Schaap-Fogler","year":"2017","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jphs.2018.10.004_bib15","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1387\/ijdb.041895ms","article-title":"Development and pathology of the hyaloid, choroidal and retinal vasculature","volume":"48","author":"Saint-Geniez","year":"2004","journal-title":"Int J Dev Biol"},{"key":"10.1016\/j.jphs.2018.10.004_bib16","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.jphs.2018.10.004_bib17","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2018.10.004_bib18","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00417-008-0914-4","article-title":"Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy","volume":"246","author":"Moradian","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jphs.2018.10.004_bib19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jphs.2018.10.004_bib20","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.ophtha.2013.12.032","article-title":"The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration","volume":"121","author":"Finger","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jphs.2018.10.004_bib21","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1248\/bpb.b14-00487","article-title":"Anti-angiogenic effects of mammalian target of rapamycin inhibitors in a mouse model of oxygen-induced retinopathy","volume":"37","author":"Yagasaki","year":"2014","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jphs.2018.10.004_bib22","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1248\/bpb.b17-00475","article-title":"Mammalian target of rapamycin (mTOR) as a potential therapeutic target in pathological ocular angiogenesis","volume":"40","author":"Nakahara","year":"2017","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jphs.2018.10.004_bib23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jphs.2015.08.010","article-title":"Retinal region-dependent susceptibility of capillaries to high-concentration oxygen exposure and vascular endothelial growth factor receptor inhibition in neonatal mice","volume":"129","author":"Iizuka","year":"2015","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2018.10.004_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jphs.2018.03.002","article-title":"Establishment of an abnormal vascular patterning model in the mouse retina","volume":"136","author":"Morita","year":"2018","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2018.10.004_bib25","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jphs.2018.10.004_bib26","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1167\/iovs.17-21416","article-title":"Apatinib, an inhibitor of vascular endothelial growth factor receptor 2, suppresses pathologic ocular neovascularization in mice","volume":"58","author":"Kim","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jphs.2018.10.004_bib27","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exer.2014.11.005","article-title":"Effects of mTOR inhibition on normal retinal vascular development in the mouse","volume":"129","author":"Yagasaki","year":"2014","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jphs.2018.10.004_bib28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1167\/iovs.02-0040","article-title":"Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression","volume":"44","author":"Feeney","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jphs.2018.10.004_bib29","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s12094-016-1494-0","article-title":"Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1\u03b1\/VEGF signals","volume":"18","author":"Zhao","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jphs.2018.10.004_bib30","doi-asserted-by":"crossref","first-page":"22211","DOI":"10.1074\/jbc.M110.180224","article-title":"Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells","volume":"286","author":"Huber","year":"2011","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jphs.2018.10.004_bib31","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jphs.2018.10.004_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10928-013-9323-3","article-title":"Sex related differences on valproic acid pharmacokinetics after oral single dose","volume":"40","author":"Ibarra","year":"2013","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861318301890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861318301890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T17:51:25Z","timestamp":1544032285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861318301890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1347861318301890"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2018.10.004","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-angiogenic effects of valproic acid in a mouse model of oxygen-induced retinopathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2018.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}